Front Line Medical Technologies Inc.

What Front Line Medical Technologies Inc. does

Front Line Medical Technologies Inc. is a privately held Canadian medical device company headquartered in Toronto, Ontario, that has developed a single commercial product: the COBRA-OS® (Control Of Bleeding, Resuscitation, Arterial Occlusion System), the first 4 French wire-free REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) catheter on the market. The device is designed for rapid, minimally invasive aortic occlusion to control non-compressible hemorrhage in trauma patients, women experiencing postpartum hemorrhage or placenta accreta spectrum complications, and military or pre-hospital casualties where time and portability are critical. Its technical differentiation rests on a 4 French ultra-low profile (reducing access-site complications versus larger REBOA catheters) and elimination of the guidewire, simplifying and accelerating deployment in time-critical settings.

The company generates revenue through direct hardware sales of COBRA-OS to hospitals, trauma centers, obstetric units, and military procurement organizations, using a consultative enterprise field-sales motion with 'Request a Demo' and 'Request More Information' CTAs on its website. Pricing is not publicly disclosed and is quote-based. Regulatory clearances have been secured across the three principal Western markets — Health Canada (February 2021), FDA 510(k) (June 2021), and CE Mark (April 2024) — plus a US National Stock Number (March 2024) for military procurement, with a UK healthcare market launch in January 2025. The company is co-founded and led by Dr. Asha Parekh (CEO, PhD in Biomedical Engineering) and Dr. Adam Power (CMO, practicing vascular surgeon, Associate Professor at Western University); it operates without traditional venture capital and has 1–10 employees.

Name

Front Line Medical Technologies Inc.

Legal name

Front Line Medical Technologies Inc.

Website

https://frontlinemedtech.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Front Line Medical Technologies is a Canadian medical device company selling COBRA-OS, the first 4 French wire-free REBOA catheter, to trauma centers, obstetric units, and military organizations for rapid hemorrhage control.

Ownership category

akta.pro rank

Product category

Medical Devices - Aortic Occlusion / Hemorrhage Control

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

akta.pro secondary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Aortic occlusion devices
• REBOA catheters
• Hemorrhage control devices
• Trauma resuscitation products
• Endovascular balloon catheters

Headquarters

HQ city

London

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

1. Medical Device Sales: Revenue generated from the sale of COBRA-OS aortic occlusion devices to hospitals, trauma centers, military organizations, and healthcare systems.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Front Line Medical Technologies designs, manufactures, and sells the COBRA-OS®, the world's smallest (4 French) wire-free REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) catheter. The device enables rapid aortic occlusion to control non-compressible hemorrhage in trauma, postpartum hemorrhage, and military/pre-hospital settings.

Product overview

Front Line Medical Technologies Inc. is a medical device company focused on a single core product: the COBRA-OS® aortic occlusion device. The company offers one unified product line centered on REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) technology. COBRA-OS® is the flagship offering—a 4 French, wire-free balloon catheter designed for rapid hemorrhage control in trauma, postpartum hemorrhage, and military/pre-hospital applications. The product portfolio consists solely of this device, which has received regulatory approvals in Canada, the US (FDA), and the EU (CE Mark), with international expansion underway to the UK and military procurement channels via NSN numbering.

Differentiator

Problem solved

Functional benefit

Products and services

• COBRA-OS® (Control Of Bleeding, Resuscitation, Arterial Occlusion System) The COBRA-OS® is the first 4 French, wire-free REBOA catheter designed for rapid aortic occlusion to control hemorrhage in critically bleeding patients. It is the smallest aortic occlusion device on the market, reducing access-site complications and enabling faster deployment. It is intended for trauma surgeons, emergency physicians, obstetricians, and military/field medics treating non-compressible torso hemorrhage, postpartum hemorrhage, and combat casualties.

Quantifiable outcome

• First-in-human study published demonstrating device feasibility

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• US Obstetrical Referral CenterscoreOthersClinical collaboration with US obstetrical referral centers for real-world data collection on COBRA-OS use in high-risk placenta accreta cases. Positive results from two US obstetrical referral centers presented at the Pan-American Society for the Placenta Accreta Spectrum 5th Annual Meeting.
• Major US Trauma CenterscoreOthersDevice adoption in major US trauma centers for non-compressible torso hemorrhage treatment, demonstrating clinical validation of COBRA-OS in trauma settings.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Prytime Medical (now Teleflex): Prytime developed the ER-REBOA catheter, the most established competitor to COBRA-OS in resuscitative endovascular balloon occlusion of the aorta. Now owned by Teleflex, Prytime/Teleflex is the primary direct competitor in the same clinical use cases (trauma, non-compressible torso hemorrhage).

Broad incumbents

• Teleflex Incorporated: Teleflex acquired Prytime Medical and sells the ER-REBOA catheter alongside a broad portfolio of vascular access, surgical, and emergency care products. Comparable as a larger incumbent operating in the same aortic occlusion and emergency vascular intervention space.
• Merit Medical Systems: Merit Medical manufactures vascular catheters, balloon devices, and trauma/embolization products used in interventional radiology and emergency vascular procedures. Comparable as a broader incumbent in the catheter-based vascular and hemorrhage control device category.
• Penumbra, Inc. Penumbra develops endovascular thrombectomy and embolization devices for vascular and neurovascular interventions. Comparable as an incumbent endovascular device maker serving overlapping physician users in acute vascular care.
• Terumo Medical Corporation: Terumo manufactures interventional and vascular access devices including catheters used in endovascular procedures. Comparable as a broad incumbent in the catheter-based vascular intervention market that intersects with REBOA users.
• Abbott Vascular: Abbott's vascular division develops endovascular and hemodynamic support products (e.g., IABP, percutaneous heart pump platforms). Comparable as a broader incumbent in catheter-based cardiovascular intervention and circulatory support.
• Edwards Lifesciences: Edwards specializes in heart valve therapies, hemodynamic monitoring, and catheter-based critical care products. Comparable as an incumbent in catheter-based cardiovascular and critical care interventions adjacent to REBOA.
• Medtronic plc: Medtronic offers mechanical circulatory support, vascular, and aortic intervention products (including endovascular aortic repair platforms). Comparable as a broad incumbent with catheter-based and mechanical circulatory support capabilities overlapping COBRA-OS's clinical context.
• Stryker Corporation: Stryker's emergency and surgical divisions produce hemorrhage control, tourniquet, and trauma care products used alongside REBOA in trauma resuscitation. Comparable as a broader incumbent serving emergency/trauma physicians and military medics with overlapping hemorrhage control products.
• ZOLL Medical Corporation (Asahi Kasei): ZOLL develops resuscitation and critical care technologies including automated CPR, defibrillation, and fluid resuscitation used in the same trauma and emergency response workflows as COBRA-OS. Comparable as a broader incumbent in resuscitation/emergency care devices.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/FrontLineCOBRA
• YouTubeyoutube.com/channel/UCBzYfdWDDRn12tUyKQ_bz-w
• Facebookfacebook.com/frontlinecobra
• LinkedInlinkedin.com/company/front-line-medical-technologies-inc
• Instagraminstagram.com/FrontLineCOBRA

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Front Line Medical Technologies Inc.